Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 71.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 221,485 shares of the company’s stock after buying an additional 92,390 shares during the period. JPMorgan Chase & Co. owned about 0.35% of Vera Therapeutics worth $9,367,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. EFG Asset Management North America Corp. raised its stake in shares of Vera Therapeutics by 59.2% during the 4th quarter. EFG Asset Management North America Corp. now owns 73,160 shares of the company’s stock worth $3,092,000 after buying an additional 27,192 shares during the period. Prudential Financial Inc. grew its stake in shares of Vera Therapeutics by 33.6% in the 4th quarter. Prudential Financial Inc. now owns 83,077 shares of the company’s stock valued at $3,513,000 after buying an additional 20,880 shares during the period. Corebridge Financial Inc. increased its stake in Vera Therapeutics by 5.8% during the fourth quarter. Corebridge Financial Inc. now owns 22,047 shares of the company’s stock worth $932,000 after acquiring an additional 1,210 shares during the last quarter. Vanguard Group Inc. raised its holdings in Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock valued at $124,737,000 after buying an additional 369,387 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $431,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

VERA has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price for the company. Guggenheim raised their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. Finally, JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Price Performance

Shares of VERA opened at $21.50 on Tuesday. The firm has a 50-day simple moving average of $27.25 and a 200-day simple moving average of $37.06. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.24 and a beta of 1.28. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.